In the 20 years since the first report of a proteolysis targeting chimeric (PROTAC) molecule,
targeted protein degradation (TPD) technologies have attempted to revolutionize the fields …

Targeted protein degradation (TPD) has been established as a viable alternative to
attenuate the function of a specific protein of interest in both biological and clinical contexts …

Targeted protein degradation (TPD) is an emerging therapeutic strategy with the potential to
modulate disease-associated proteins that have previously been considered undruggable …

Targeted protein degradation (TPD) has emerged in the past decade as a major new drug
modality to remove intracellular proteins with bispecific small molecules that recruit the …

Highlights•Targeted-protein degradation supports fundamental discovery and drug
development.•Biologics-based degraders target intracellular, extracellular, and membrane …

Traditional drug discovery mainly focuses on direct regulation of protein activity. The
development and application of protein activity modulators, particularly inhibitors, has been …

Targeted protein degradation (TPD) aids in developing novel bifunctional small-molecule
degraders and eliminates proteins of interest. The TPD approach shows promising results in …

Of late, targeted protein degradation (TPD) has surfaced as a novel and innovative chemical
tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates …

Proteolysis‐targeting chimeric molecules (PROTACs) represent an emerging technique that
is receiving much attention for therapeutic intervention. The mechanism is based on the …

With the discovery of PROteolysis TArgeting Chimeras (PROTACs) twenty years ago,
targeted protein degradation (TPD) has changed the landscape of drug development …